Quantitative proteomics reveals an altered cystic fibrosis in vitro bronchial epithelial secretome

American Journal of Respiratory Cell and Molecular Biology

Volumn 53, Issue 1, 2015, Pages 22-32

  Peters Hall, Jennifer R ^a,b   Brown, Kristy J ^a,b   Pillai, Dinesh K ^a,b   Tomney, Amarel ^b   Garvin, Lindsay M ^a,b   Wu, Xiaofang ^a,b   Rose, Mary C ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Bronchial epithelial secretions; Cystic fibrosis; Innate immunity; Quantitative proteomics; Secretome

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 5; CATHEPSIN B; CATHEPSIN D; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT FACTOR I; FIBRONECTIN; GALECTIN 3; GELATINASE B; GELSOLIN; HISTONE H2B; HISTONE H4; KALLIKREIN; KALLIKREIN 10; KALLIKREIN 11; LAMININ; LAMININ SUBUNIT BETA3; MUCIN 5AC; MUCIN 5B; PERLECAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; PROTEIN S 100; PROTEOME; SERINE PROTEINASE INHIBITOR; SERPIN B3; SERPIN B4; SERPIN B5; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ARTICLE; BRONCHUS MUCOSA; BRONCHUS SECRETION; CELL STRUCTURE; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOSKELETON; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MASS SPECTROMETRY; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEOMICS; QUANTITATIVE ANALYSIS; BRONCHUS; CELL LINE; CHRONIC DISEASE; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY; RESPIRATORY TRACT MUCOSA; SECRETION (PROCESS);

BACTERIA (MICROORGANISMS);

BRONCHI; CELL LINE; CHRONIC DISEASE; CYSTIC FIBROSIS; HUMANS; INFLAMMATION; PROTEOME; PROTEOMICS; RESPIRATORY MUCOSA;

EID: 84936995520     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0256RC     Document Type: Article

References (77)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001.
2. Tabcharani JA, Chang XB, Riordan JR, Hanrahan JW. The cystic fibrosis transmembrane conductance regulator chloride channel: iodide block and permeation. Biophys J 1992;62:1-4.
3. Linsdell P, Hanrahan JW. Glutathione permeability of CFTR. Am J Physiol 1998;275:C323-C326.
4. Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008;372:415-417.
5. Kreda SM, Davis CW, Rose MC. CFTR, mucins, and mucus obstruction in cystic fibrosis. Cold Spring Harb Perspect Med 2012;2:a009589.
6. Boat TF, Welsh MJ, Beaudet AL. Cystic Fibrosis. In: Charles R. Scriver, Arthur L. Beaudet, William S. Sly, David Valle, editors. The metabolic basis of inherited disease, 6 ed. New York: McGraw-Hill; 1989. pp. 2649-2678.
7. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
8. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012;18:509-519.
9. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DWH. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082.
10. Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM; AREST CF Investigators. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013;368:1963-1970.
11. Meyerholz DK, Stoltz DA, Namati E, Ramachandran S, Pezzulo AA, Smith AR, Rector MV, Suter MJ, Kao S, McLennan G, et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. Am J Respir Crit Care Med 2010;182:1251-1261.
12. Stoltz DA, Rokhlina T, Ernst SE, Pezzulo AA, Ostedgaard LS, Karp PH, Samuel MS, Reznikov LR, Rector MV, Gansemer ND, et al. Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs. J Clin Invest 2013;123:2685-2693.
13. Keiser NW, Birket SE, Evans IA, Tyler SR, Crooke AK, Sun X, Zhou W, Nellis JR, Stroebele EK, Chu KK, et al. Defective innate immunity and hyper-inflammation in newborn CFTR-knockout ferret lungs. Am J Respir Cell Mol Biol (In press)
14. Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP, Davis GJ, Hanfland RA, Wohlford-Lenane C, Dohrn CL, Bartlett JA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010;2:29ra31.
15. Sun X, Sui H, Fisher JT, Yan Z, Liu X, Cho HJ, Joo NS, Zhang Y, Zhou W, Yi Y, et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J Clin Invest 2010;120:3149-3160.
16. Bals R, Weiner DJ, Meegalla RL, Accurso F, Wilson JM. Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid. Am J Respir Cell Mol Biol 2001;25:21-25.
17. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85:229-236.
18. Moraes TJ, Plumb J, Martin R, Vachon E, Cherepanov V, Koh A, Loeve C, Jongstra-Bilen J, Zurawska JH, Kus JV, et al. Abnormalities in the pulmonary innate immune system in cystic fibrosis. Am J Respir Cell Mol Biol 2006;34:364-374.
19. Diamond G, Legarda D, Ryan LK. The innate immune response of the respiratory epithelium. Immunol Rev 2000;173:27-38.
20. Ollero M, Brouillard F, Edelman A. Cystic fibrosis enters the proteomics scene: new answers to old questions. Proteomics 2006;6:4084-4099.
21. Gharib SA, Vaisar T, Aitken ML, Park DR, Heinecke JW, Fu X. Mapping the lung proteome in cystic fibrosis. J Proteome Res 2009;8:3020-3028.
22. Wu R, Zhao YH, Chang MM. Growth and differentiation of conducting airway epithelial cells in culture. Eur Respir J 1997;10:2398-2403.
23. nd ed. Totowa, NJ: Humana Press Inc.; 2004. pp. 183-206.
24. Sarkadi B, Bauzon D, Huckle WR, Earp HS, Berry A, Suchindran H, Price EM, Olson JC, Boucher RC, Scarborough GA. Biochemical characterization of the cystic fibrosis transmembrane conductance regulator in normal and cystic fibrosis epithelial cells. J Biol Chem 1992;267:2087-2095.
25. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-1015.
26. Randell SH, Fulcher ML, O'Neal W, Olsen JC. Primary epithelial cell models for cystic fibrosis research. Methods Mol Biol 2011;742:285-310.
27. Kesimer M, Kirkham S, Pickles RJ, Henderson AG, Alexis NE, Demaria G, Knight D, Thornton DJ, Sheehan JK. Tracheobronchial air-liquid interface cell culture: a model for innate mucosal defense of the upper airways? Am J Physiol Lung Cell Mol Physiol 2009;296:L92-L100.
28. Hathout Y, Flippin J, Fan C, Liu P, Csaky K. Metabolic labeling of human primary retinal pigment epithelial cells for accurate comparative proteomics. J Proteome Res 2005;4:620-627.
29. Fulcher ML, Gabriel SE, Olsen JC, Tatreau JR, Gentzsch M, Livanos E, Saavedra MT, Salmon P, Randell SH. Novel human bronchial epithelial cell lines for cystic fibrosis research. Am J Physiol Lung Cell Mol Physiol 2009;296:L82-L91.
30. Peters KW, Okiyoneda T, Balch WE, Braakman I, Brodsky JL, Guggino WB, Penland CM, Pollard HB, Sorscher EJ, Skach WR, et al. CFTR Folding Consortium: methods available for studies of CFTR folding and correction. Methods Mol Biol 2011;742:335-353.
31. Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 2013;41:D377-D386.
32. Bendtsen JD, Jensen LJ, Blom N, Von Heijne G, Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel 2004;17:349-356.
33. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods 2011;8:785-786.
34. Brown KJ, Seol H, Pillai DK, Sankoorikal BJ, Formolo CA, Mac J, Edwards NJ, Rose MC, Hathout Y. The human secretome atlas initiative: implications in health and disease conditions. Biochim Biophys Acta 2013;1834:2454-2461.
35. Pillai DK, Sankoorikal BJ, Johnson E, Seneviratne AN, Zurko J, Brown KJ, Hathout Y, Rose MC. Directional secretomes reflect polarity-specific functions in an in vitro model of human bronchial epithelium. Am J Respir Cell Mol Biol 2014;50:292-300.
36. Formolo CA, Williams R, Gordish-Dressman H, MacDonald TJ, Lee NH, Hathout Y. Secretome signature of invasive glioblastoma multiforme. J Proteome Res 2011;10:3149-3159.
37. Cantin AM, Hanrahan JW, Bilodeau G, Ellis L, Dupuis A, Liao J, Zielenski J, Durie P. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006;173:1139-1144.
38. Clunes LA, Davies CM, Coakley RD, Aleksandrov AA, Henderson AG, Zeman KL, Worthington EN, Gentzsch M, Kreda SM, Cholon D, et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J 2012;26:533-545.
39. Kesimer M, Scull M, Brighton B, DeMaria G, Burns K, O'Neal W, Pickles RJ, Sheehan JK. Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense. FASEB J 2009;23:1858-1868.
40. Brown KJ, Formolo CA, Seol H, Marathi RL, Duguez S, An E, Pillai D, Nazarian J, Rood BR, Hathout Y. Advances in the proteomic investigation of the cell secretome. Expert Rev Proteomics 2012;9:337-345.
41. Pangburn MK, Müller-Eberhard HJ. The alternative pathway of complement. Springer Semin Immunopathol 1984;7:163-192.
42. Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, Mitchell LM, Hourcade DE, Hannan JP, Kovacs JM, et al. Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest 2013;123:2218-2230.
43. Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol 2010;298:L715-L731.
44. Regamey N, Jeffery PK, Alton EW, Bush A, Davies JC. Airway remodelling and its relationship to inflammation in cystic fibrosis. Thorax 2011;66:624-629.
45. Tirouvanziam R, de Bentzmann S, Hubeau C, Hinnrasky J, Jacquot J, Péault B, Puchelle E. Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 2000;23:121-127.
46. Schiller KR, Maniak PJ, O'Grady SM. Cystic fibrosis transmembrane conductance regulator is involved in airway epithelial wound repair. Am J Physiol Cell Physiol 2010;299:C912-C921.
47. Pattison SH, Elborn JS. Protein biomarkers in cystic fibrosis research: where next? Genome Med 2010;2:88.
48. Henderson AG, Ehre C, Button B, Abdullah LH, Cai LH, Leigh MW, DeMaria GC, Matsui H, Donaldson SH, Davis CW, et al. Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. J Clin Invest 2014;124:3047-3060.
49. Preciado D, Goyal S, Rahimi M, Watson AM, Brown KJ, Hathout Y, Rose MC. MUC5B Is the predominant mucin glycoprotein in chronic otitis media fluid. Pediatr Res 2010;68:231-236.
50. Kirkham S, Sheehan JK, Knight D, Richardson PS, Thornton DJ. Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J 2002;361:537-546.
51. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006;86:245-278.
52. Jacquot J, Puchelle E, Hinnrasky J, Fuchey C, Bettinger C, Spilmont C, Bonnet N, Dieterle A, Dreyer D, Pavirani A, et al. Localization of the cystic fibrosis transmembrane conductance regulator in airway secretory glands. Eur Respir J 1993;6:169-176.
53. Wioland MA, Fleury-Feith J, Corlieu P, Commo F, Monceaux G, Lacau-St-Guily J, Bernaudin JF. CFTR, MDR1, and MRP1 immunolocalization in normal human nasal respiratory mucosa. J Histochem Cytochem 2000;48:1215-1222.
54. Kreda SM, Mall M, Mengos A, Rochelle L, Yankaskas J, Riordan JR, Boucher RC. Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol Biol Cell 2005;16:2154-2167.
55. LeSimple P, Goepp J, Palmer ML, Fahrenkrug SC, O'Grady SM, Ferraro P, Robert R, Hanrahan JW. Cystic fibrosis transmembrane conductance regulator is expressed in mucin granules from Calu-3 and primary human airway epithelial cells. Am J Respir Cell Mol Biol 2013;49:511-516.
56. Shen BQ, Finkbeiner WE, Wine JJ, Mrsny RJ, Widdicombe JH. Calu-3: a human airway epithelial cell line that shows cAMP-dependent Cl- secretion. Am J Physiol 1994;266:L493-L501.
57. Balfour-Lynn IM. The protease-antiprotease battle in the cystic fibrosis lung. J R Soc Med 1999;92:23-30.
58. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
59. Hajj R, Lesimple P, Nawrocki-Raby B, Birembaut P, Puchelle E, Coraux C. Human airway surface epithelial regeneration is delayed and abnormal in cystic fibrosis. J Pathol 2007;211:340-350.
60. Fujita J, Rennard SI. Fibronectin in the lung. In: Carsons SE, editor. Fibronectin in health and disease. Boca Raton: CRC Press, Inc.; 1989. p. 217.
61. Beckmann JD, Illig M, Romberger D, Rennard SI. Induction of fibronectin gene expression by transforming growth factor beta-1 is attenuated in bronchial epithelial cells by ADP-ribosyltransferase inhibitors. J Cell Physiol 1992;152:274-280.
62. Hocking DC. Fibronectin matrix deposition and cell contractility: implications for airway remodeling in asthma. Chest 2002;122(Suppl):275S-278S.
63. Tabary O, Escotte S, Couetil JP, Hubert D, Dusser D, Puchelle E, Jacquot J. Genistein inhibits constitutive and inducible NFkappaB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells. Am J Pathol 1999;155:473-481.
64. Vij N, Mazur S, Zeitlin PL. CFTR is a negative regulator of NFkappaB mediated innate immune response. PLoS One 2009;4:e4664.
65. Veit G, Bossard F, Goepp J, Verkman AS, Galietta LJ, Hanrahan JW, Lukacs GL. Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia. Mol Biol Cell 2012;23:4188-4202.
66. Machen TE. Innate immune response in CF airway epithelia: hyperinflammatory? Am J Physiol Cell Physiol 2006;291:C218-C230.
67. Fujisawa T, Velichko S, Thai P, Hung L-Y, Huang F, Wu R. Regulation of airway MUC5AC expression by IL-1beta and IL-17A; the NF-kappaB paradigm. J Immunol 2009;183:6236-6243.
68. Chen Y, Garvin LM, Nickola TJ, Watson AM, Colberg-Poley AM, Rose MC. IL-1β induction of MUC5AC gene expression is mediated by CREB and NF-κB and repressed by dexamethasone. Am J Physiol Lung Cell Mol Physiol 2014;306:L797-L807.
69. Fujisawa T, Chang MM, Velichko S, Thai P, Hung LY, Huang F, Phuong N, Chen Y, Wu R. NF-κB mediates IL-1β and IL-17A-induced MUC5B expression in the airway epithelial cells. Am J Respir Cell Mol Biol 2011;45:246-252.
70. Lee BH, Park SY, Kang KB, Park RW, Kim IS. NF-kappaB activates fibronectin gene expression in rat hepatocytes. Biochem Biophys Res Commun 2002;297:1218-1224.
71. Moon MR, Parikh AA, Pritts TA, Fischer JE, Cottongim S, Szabo C, Salzman AL, Hasselgren PO. Complement component C3 production in IL-1beta-stimulated human intestinal epithelial cells is blocked by NF-kappaB inhibitors and by transfection with ser 32/36 mutant IkappaBalpha. J Surg Res 1999;82:48-55.
72. Chou YC, Sheu JR, Chung CL, Chen CY, Lin FL, Hsu MJ, Kuo YH, Hsiao G. Nuclear-targeted inhibition of NF-kappaB on MMP-9 production by N-2-(4-bromophenyl) ethyl caffeamide in human monocytic cells. Chem Biol Interact 2010;184:403-412.
73. Zhang F, Wang Q, Ye L, Feng Y, Zhang X, Hepatitis B virus X protein upregulates expression of calpain small subunit 1 via nuclear factor-kappaB/p65 in hepatoma cells. J Med Virol 2010;82:920-928.
74. Hamer I, Delaive E, Dieu M, Abdel-Sater F, Mercy L, Jadot M, Arnould T. Up-regulation of cathepsin B expression and enhanced secretion in mitochondrial DNA-depleted osteosarcoma cells. Biol Cell 2009;101:31-41.
75. Jeong IK, Oh H, Park SJ, Kang JH, Kim S, Lee MS, Kim MJ, Hwang YC, Ahn KJ, Chung HY, et al. Inhibition of NF-κB prevents high glucose-induced proliferation and plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Exp Mol Med 2011;43:684-692.
76. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 2004;279:5059-5065.
77. Jijon HB, Madsen KL, Walker JW, Allard B, Jobin C. Serum amyloid A activates NF-kappaB and proinflammatory gene expression in human and murine intestinal epithelial cells. Eur J Immunol 2005;35:718-726.